Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group.

MLA

Terheyden, P., et al. “Chemoimmunotherapy for Cutaneous Melanoma with Dacarbazine and Epifocal Contact Sensitizers: Results of a Nationwide Survey of the German Dermatologic Co-Operative Oncology Group.” Journal of Cancer Research and Clinical Oncology, vol. 133, no. 7, July 2007, pp. 437–44. EBSCOhost, https://doi.org/10.1007/s00432-006-0182-9.

APA

Terheyden, P., Kortüm, A.-K., Schulze, H.-J., Durani, B., Remling, R., Mauch, C., Junghans, V., Schadendorf, D., Beiteke, U., Jünger, M., Becker, J. C., & Bröcker, E.-B. (2007). Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group. Journal of Cancer Research and Clinical Oncology, 133(7), 437–444. https://doi.org/10.1007/s00432-006-0182-9

Chicago

Terheyden, P, A-K Kortüm, H-J Schulze, B Durani, R Remling, C Mauch, V Junghans, et al. 2007. “Chemoimmunotherapy for Cutaneous Melanoma with Dacarbazine and Epifocal Contact Sensitizers: Results of a Nationwide Survey of the German Dermatologic Co-Operative Oncology Group.” Journal of Cancer Research and Clinical Oncology 133 (7): 437–44. doi:10.1007/s00432-006-0182-9.